Critical Care Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Sepsis, Organ Dysfunction and Resuscitation (SODIR) Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
Perfusion. 2023 May;38(1_suppl):40-43. doi: 10.1177/02676591231160462. Epub 2023 Feb 28.
Patients with extracorporeal membrane oxygenation (ECMO) support do frequently receive broad-spectrum antibiotics, due to the high frequency of infection by multidrug resistant microorganisms. The extracorporeal circuit can alter the pharmacokinetics (PK) of administered drugs, and in the case of antibiotics this may lead to treatment failure. Cefiderocol is a new cephalosporin that exhibits excellent in vitro activity against many multidrug-resistant (MDR) microorganisms, but there is no published data about the modifications of its PK in patients with ECMO support. Herein we report the results of a pharmacokinetic investigation of cefiderocol in a critically ill patient receiving extracorporeal respiratory support.
接受体外膜氧合（ECMO）支持的患者经常接受广谱抗生素治疗，这是由于多药耐药微生物感染的频率很高。体外循环可以改变给予的药物的药代动力学（PK），在抗生素的情况下，这可能导致治疗失败。头孢地尔是一种新的头孢菌素，对许多多药耐药（MDR）微生物具有出色的体外活性，但目前尚无关于 ECMO 支持患者中其 PK 变化的发表数据。在此，我们报告了一名接受体外呼吸支持的危重症患者头孢地尔药代动力学研究的结果。
